Axsome Therapeutics (NASDAQ:AXSM) Price Target Lowered to $200.00 at HC Wainwright

Axsome Therapeutics (NASDAQ:AXSM – Get Rating) had its target price reduced by HC Wainwright from $210.00 to $200.00 in a report released on Monday morning, The Fly reports. HC Wainwright also issued estimates for Axsome Therapeutics’ Q1 2023 earnings at ($1.40) EPS, Q2 2023 earnings at ($1.40) EPS, Q3 2023 earnings at ($1.29) EPS, Q4 […]

Related Keywords

United States ,America ,Piper Sandler ,Axsome Therapeutics Company Profile ,Axsome Therapeutics Inc ,Brinker Capital Investments ,Health Sciences ,Tower Research Capital ,Axsome Therapeutics ,Get Rating ,Moderate Buy ,Therapeutics Trading Down ,Capital Investments ,Research Capital ,Products Overview ,Pipeline Overview ,Axsome Therapeutics Daily ,Nasdaq Axsm ,Axsm ,Medical ,Lower Price Target ,Hc Wainwright ,